Eli Lilly stock jumps 10% on annual guidance hike, strong Q2 top and bottom line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly (LLY) PT Raised to $1,150 at BofA Securities
August 9, 2024 5:56 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Eli Lilly (NYSE: LLY) to $1,150.00 (from $1,000.00) while maintaining a Buy rating.
The analyst comments "LLY shares traded with strength today (+9.5%; DRG index: +4%) following the continued outperformance from Lillys incretin portfolio, including Mounjaro (Type 2 diabetes) and Zepbound (obesity). Importantly, given managements... More
Eli Lilly & Co. (LLY) Tops Q2 EPS by $1.17, Beats on Revenue; Offers Upbeat FY24 Guidance
August 8, 2024 6:47 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $3.92, $1.17 better than the analyst estimate of $2.75. Revenue for the quarter came in at $11.3 billion versus the consensus estimate of $10 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2024 EPS of $16.10-$16.60, versus the... More
